Drugmaker Aurobindo Pharma reported consolidated net revenue for the March quarter declined greater than 12% to ₹505.9 crore.
The decrease net revenue got here whilst revenue from operations elevated greater than 11% to ₹6,472.96 crore. Aiding the rise was a 51% improve in Formulations gross sales to ₹592 crore in ‘Growth Markets,’ together with India, which additionally helped blunt the influence of a 32% decline in ARV revenue to ₹159 crore in the course of the quarter.
During the quarter, U.S. formulations revenue elevated 11.6% YoY to ₹3,045 crore, whereas Europe formulations revenue stood at ₹1,660 crore, a rise of seven.7%, the corporate mentioned.
“We saw decent performance in the quarter on the back of stable demand and pricing environment across our portfolio and geographies,” vice-chairman and MD Ok. Nityananda Reddy mentioned in a launch.
For the fiscal, the corporate reported a greater than 27% decline in net revenue to ₹1,927.6 crore whilst revenue from operations elevated 6% to ₹24,855.3 crore.
